[go: up one dir, main page]

CL2007003065A1 - Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others - Google Patents

Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others

Info

Publication number
CL2007003065A1
CL2007003065A1 CL2007003065A CL2007003065A CL2007003065A1 CL 2007003065 A1 CL2007003065 A1 CL 2007003065A1 CL 2007003065 A CL2007003065 A CL 2007003065A CL 2007003065 A CL2007003065 A CL 2007003065A CL 2007003065 A1 CL2007003065 A1 CL 2007003065A1
Authority
CL
Chile
Prior art keywords
benzodioxane
anxiety
depression
pharmaceutical composition
understand
Prior art date
Application number
CL2007003065A
Other languages
Spanish (es)
Inventor
Gary Paul Stack
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2007003065A1 publication Critical patent/CL2007003065A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos derivados de benzodioxano; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar una enfermedad seleccionada entre trastornos psicóticos, tales como ansiedad, depresión, trastorno bipolar, síndrome premenstrual, entre otros.Compounds derived from benzodioxane; pharmaceutical composition comprising said compounds; and its use to treat a disease selected from psychotic disorders, such as anxiety, depression, bipolar disorder, premenstrual syndrome, among others.

CL2007003065A 2006-10-24 2007-10-24 Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others CL2007003065A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85405506P 2006-10-24 2006-10-24

Publications (1)

Publication Number Publication Date
CL2007003065A1 true CL2007003065A1 (en) 2008-01-25

Family

ID=38941237

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007003065A CL2007003065A1 (en) 2006-10-24 2007-10-24 Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others

Country Status (4)

Country Link
AR (1) AR063373A1 (en)
CL (1) CL2007003065A1 (en)
TW (1) TW200823187A (en)
WO (1) WO2008052086A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5520051B2 (en) 2007-11-15 2014-06-11 武田薬品工業株式会社 Condensed pyridine derivatives and uses thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP6080226B2 (en) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzodioxane for inhibiting leukotriene production in combination with other active substances
WO2014014874A1 (en) 2012-07-17 2014-01-23 Boehringer Ingelheim International Gmbh Pyrazole derivatives which inhibit leukotriene production
EP2948149A4 (en) 2013-01-23 2016-12-14 Aldeyra Therapeutics Inc DISEASES RELATED TO TOXIC ALDEHYDE AND TREATMENT
US9573957B2 (en) 2013-07-15 2017-02-21 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
JP6353899B2 (en) 2013-07-15 2018-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhibitors of leukotriene production
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
MX2018002155A (en) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc DEUTERATED COMPOUNDS AND USES OF THE SAME.
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (en) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド Polymorphic compounds and their use
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
IL309524A (en) * 2021-07-02 2024-02-01 Aldeyra Therapeutics Inc Heterocyclic aldehyde scavenging compounds and uses thereof
JP2024542963A (en) 2021-11-01 2024-11-19 アルカヘスト，インコーポレイテッド Benzodioxane Modulators of Leukotriene A4 Hydrolase (LTA4H) for the Prevention and Treatment of Age-Related Diseases - Patent application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791675B1 (en) * 1999-03-30 2001-05-04 Synthelabo DERIVATIVES OF N- [2- (4-AMINOPHENYL) ETHYL] -2,3-DIHYDRO-1,4- BENZODIOXINNE-2-METHANAMINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
PT1204658E (en) * 1999-07-29 2003-08-29 Lilly Co Eli SEROTONIN BENZOFURILPIPERAZINE AGONISTS
AR038762A1 (en) * 2000-10-16 2005-01-26 Hoffmann La Roche DERIVATIVES OF INDOLINA, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
SE0201544D0 (en) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
AU2006239930A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof

Also Published As

Publication number Publication date
AR063373A1 (en) 2009-01-21
WO2008052086A1 (en) 2008-05-02
TW200823187A (en) 2008-06-01

Similar Documents

Publication Publication Date Title
CL2007003065A1 (en) Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others
CL2007002971A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
CL2012001673A1 (en) Substituted benzamide derivative compounds, as modulators of taar; preparation procedure; pharmaceutical composition; and its use in the treatment of depression, anxiety disorders, bipolar disorder, schizophrenia, epilepsy, migraine, Alzheimer's disease, metabolic disorders, among others.
CL2008000434A1 (en) COMPOUNDS DERIVED FROM 2-AMINO-OXAZOLINAS; OBTAINING PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DEPRESSION, ANXIETY, STRESS, BIPOLAR DISORDER, AMONG OTHERS.
ECSP067021A (en) COMPOUNDS AND COMPOSITIONS AS RECEPTOR MODULATORS ACTIVATED BY PEROXISOM PROLIFERATOR (PPAR)
CL2011000144A1 (en) Compounds derived from benzo (1,4) dioxin-2-ylmethyl-sulfamide; pharmaceutical compositions containing them; process to prepare them and use in the treatment of anxiety, epilepsy, pain, substance abuse, related disorders, among others.
CL2007002970A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
HN2008001720A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
BR122019021238B8 (en) use of an interleukin-6 (il-6) receptor inhibitor in the treatment of graft versus host disease (gvhd)
CL2008001114A1 (en) Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others.
CL2007003832A1 (en) COMPOUNDS DERIVED FROM AZAESPIRO; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO PREVENT AND TREAT ANXIETY, DEPRESSIVE DISORDERS, AMONG OTHER DISEASES.
ECSP10010684A (en) MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY.
UY32926A (en) COMPOUNDS AS ANTAGONISTS OF LISOPHOSPHATIDIC ACID RECEPTORS
UY28876A1 (en) SUBSTITUTED MORPHOLINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
CL2011000527A1 (en) Compounds derived from benzofuran; pharmaceutical composition that includes them; and their use in the treatment of hepatitis c.
CL2011001263A1 (en) Compounds derived from optionally substituted pyrimidinones; pharmaceutical composition that includes them; and its use as phosphodiesterase 1 (pde1) inhibitors for the treatment of diseases involving disorders of the intracellular trajectory of the dopamine d1 receptor such as parkinson's, Alzheimer's, depression, bipolar disease, hypertension, glaucoma.
CL2008002268A1 (en) Compounds derived from amides, modulators of the taar1 receptor; obtaining process; pharmaceutical composition; and use in the treatment of diseases such as depression, anxiety, stress, among others.
ECSP099061A (en) BENZOFUR- AND BENZOTIENOPIRIMIDINE MODULATORS
CL2008001465A1 (en) Compounds derived from [2,1,3] benzoxadiazole-5-carboxamides, modulators of ampa receptors; pharmaceutical compositions; and its use in the treatment of hypoglutamatergic conditions, cognitive disorders, parkinson's disease, adhd, rett syndrome, respiratory depression, fragile x syndrome, and Alzheimer's disease.
CL2008002247A1 (en) Compounds derived from phenyl amide; Preparation process; pharmaceutical composition containing them; and its use in the preparation of drugs for the treatment of sleep disorders, narcolepsy and psychiatric disorders, among others.
AR047759A1 (en) FENIL DERIVATIVES - PIPERAZINE AS MODULATORS OF MUSCARNIC RECEPTORS
CL2011001427A1 (en) Compounds derived from 4-azetidinyl-1-heteroaryl-cyclohexanol; pharmaceutical composition; and use in the treatment of diseases such as epoc, atherosclerosis, rheumatoid arthritis, among others.
CL2010001566A1 (en) Compound derived from piperidinyl, modulator of the activity of chemokine receptors; pharmaceutical composition that includes them; and its use in the treatment of inflammatory, allergic, autoimmune diseases.
CL2012000097A1 (en) Compounds derived from 3-phenoxymethylpyrrolidine, serotonin-norepinephrine reuptake inhibitors; preparation procedure; intermediate compounds; pharmaceutical composition comprising it; and its use in the treatment of pain disorders, depression, among others.
CL2011000184A1 (en) Compounds derived from 1,6-dihydro-2h-3-oxa-6-aza-as-indacene; melatonin receptor agonist; process for the preparation of compounds; pharmaceutical composition comprising the compounds; and their use of the compounds in the preparation of drugs.